HER-3在乳腺癌中的表达及其与ER、PR、HER-2的关系

目的研究乳腺癌组织中表皮生长因子受体-3（HER-3）的表达，并分析其与乳腺癌临床病理、预后及雌激素受体（ER）、孕激素受体（PR）、表皮生长因子受体-2（HER-2）的关系，以及对乳腺癌患者HER-3、HER-2、ER、PR检测的意义。方法收集2006年1月至10月大连医科大学附属第二医院，术前未经放化疗、术后行内分泌治疗，资料完整的女性乳腺癌139例。采用免疫组化的方法检测患者组织中HER-3的表达。从病历中获得ER、PR、HER-2的表达、组织学分级、肿瘤大小及淋巴结转移等资料。比较各观察指标与HER-3表达的关系。结果①HER-3表达阳性率30．2％（42／139），HER-2表达阳性率为42．5％（59／139），ER阳性率66．9％（93／139），PR阳性率59．7％（83／139）；②各统计项与患者年龄无相关性（P〉0．05）；③HER-3与肿瘤的大小、淋巴结转移、组织学分级、5年生存率、HER-2相关（P〈0．05），与ER、PR无相关性（P〉0．05）；@HER-3与HER-2的联合与肿瘤的大小、腋窝淋巴结转移、组织学分级、ER及PR相关（P〈0．05）。结论HER-3的检测对乳腺癌的诊断、预后评估有重要意义，并可预测HER．2的表达情况；检测乳腺癌组织中HER-3、HER-2、ER、PR对肿瘤的早期诊断、早治疗、用药、预后及新药物的研发有重要意义。

Expression of HER-3 in breast cancer tissues and its relationship with ER, PR and HER-2

Objective To study the expression of HER-3 in breast cancer patients and analyze its relationship with the clinical pathology and prognosis of breast cancer, ER, PR and HER-2. Methods Data of 139 female breast cancer patients undergoing operations at the Second Hospital of Dalian Medical University from Jan. 2006 to Oct. 2006 were collected. These 139 patients didn＇t have preoperative chemotherapy or radiation therapy, but had postoperative endocrine therapies. Immunohistochemisty was used to detect the expression of HER-3 in the 139 patients. Data like the expression of ER, PR and HER-2, histological grading, tumor size and lymph node metastasis were obtained from their medical records. The relationship between indicators and breast cancer was analyzed. Results （!）The positive expression rate of HER-3, HER-2, ER, and PR was 30. 2% （42/139） , 42. 5% （59/139） ,66. 9% （93/139） , and 59.7% （83/139）respectively. （~）The statistical items had no relation with patients＇ age（ P 〉 0.05 ）. ①HER-3 expression was correlated with tumor sizes, lymph node metastasis, histological grading ,5 year survival rate and HER-2 expression（ P 〈 0. 05 ） , and had no relation with ER or PR（ P 〉 0. 05 ）. ②The combined expression of HER-3 ＆ HER-2 was correlated with tumor sizes, axillary lymph node metastasis, histological grading, ER and PR. （ P 〈 0. 05 ）. Conclusions HER-3 detection is of great significance for the diagnosis and prognosis of breast cancer. The combined examination of HER-3, HER-2, ER, and PR in breast cancer tissues is of clinical significance for early diagnosis/treatment, medication and prognosis of the tumor, as well as for new drug research and development.